Prysmian Nears Deal to Acquire Atkore in Potential All-Cash Takeover 
Novo Nordisk Eyes Turnaround as Oral Wegovy Challenges Eli Lilly in Weight-Loss Drug Race 
Chery Invests $75 Million in KG Mobility to Expand Global Automotive Partnership 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Jetstar to Charge for Overhead Cabin Bags From February 
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales 
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch 
Palantir Stock Soars as AI Demand Drives Strong Q2 Earnings and Higher 2026 Outlook 
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions 
Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves 
Trump Urges Exxon, Chevron to Cut Gas Prices After Record Oil Profits 
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal 
BYD July Global Vehicle Sales Rise 22% as Overseas Demand Surges 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets 
DHL Q2 Profit Jumps 24% as Express Business Drives Growth 
Apple Restores Telegram to App Store After Content Policy Violation 
NEW ORLEANS, March 28, 2018 -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 28, 2018 to file lead plaintiff applications in a securities class action lawsuit against Solid Biosciences Inc. (Nasdaq:SLDB), if they purchased the Company’s shares between January 25, 2018, and March 14, 2018 (the “Class Period”) or in its January 25, 2018 initial public offering (“IPO”). This action is pending in the United States District Court for the District of Massachusetts.
What You May Do
If you purchased shares of Solid Biosciences and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-sldb/ to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 28, 2018.
About the Lawsuit
Solid Biosciences and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On January 30, 2018, a report co-authored by a former scientific advisor of the Company revealed risks of high systemic dosing using the Company’s delivery system, AAV or adeno-associated virus, for its lead drug candidate SGT-001. Then, on March 14, 2018, the Company disclosed a clinical hold placed on the SGT-001 trial by the FDA relating to adverse events.
On this news, the price of Solid Biosciences’ shares plummeted over 60% to $9.32/share on March 15, 2018.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact:
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
[email protected]
1-877-515-1850
206 Covington St.
Madisonville, LA 70447
